

IFU

PATENT  
Customer No. 22,852  
Attorney Docket No. 02481.1707-01

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: )  
)  
Bernward SCHÖLKENS et al. ) Group Art Unit: 1614  
)  
Application No.: 10/694,001 ) Examiner: R. Henley, III  
)  
Filed: October 28, 2003 )  
)  
For: USE OF INHIBITORS OF THE )  
RENIN-ANGIOTENSIN SYSTEM IN )  
THE PREVENTION OF )  
CARDIOVASCULAR EVENTS )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance.

Each document listed in this Information Disclosure Statement was first cited in a communication from the Russian Patent Office in a counterpart foreign application, and this Information Disclosure Statement is being filed within three months of the mailing date of that communication.

Copies of the listed documents are attached.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: September 22, 2004

By:   
Steven J. Scott  
Reg. No. 43,911



INFORMATION DISCLOSURE CITATION

Atty. Docket No.	02481.1707-01	Appln. No.	10/694,001
Applicant	Bernward SCHÖLKENS et al.		
Filing Date	October 28, 2003	Group:	1614

U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Jonathan Leor, et al., "Aspirin and Mortality in Patients Treated With Angiotensin-Converting Enzyme Inhibitors," Journal of the American College of Cardiology, Vol. 33, No. 7, pp. 1920-1925, 1999
	Wu Ning et al., "Secondary prevention of cardiac events following myocardial infarction: effects of atenolol and enalapril," Chinese Medical Journal, 110(8), pp. 602-606, 1997
	Paul N. Durrington, "Diabetic dyslipidaemia," Bailliere's Clinical Endocrinology and Metabolism, Vol. 13, No. 2, pp. 265-278, 1999
	Robert A. Kreisberg, "Diabetic Dyslipidemia," American Journal of Cardiology, Vol. 82, (12A), pp. 67U-73U, 1998

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce